Relay Therapeutics, Inc. (RLAY) Bundle
Understanding Relay Therapeutics, Inc. (RLAY) Revenue Streams
Revenue Analysis
Relay Therapeutics, Inc. reported total revenue of $46.1 million for the fiscal year 2023, primarily derived from collaboration and licensing agreements.
| Revenue Source | Amount (2023) | Percentage |
|---|---|---|
| Collaboration Revenue | $41.2 million | 89.4% |
| Licensing Agreements | $4.9 million | 10.6% |
Key revenue performance metrics for the company include:
- Year-over-year revenue growth: 37.5%
- Research and development collaboration income: $38.7 million
- Total contract revenue for 2023: $46.1 million
Revenue breakdown by key strategic partnerships:
| Partner | Collaboration Revenue | Contract Type |
|---|---|---|
| Genentech | $24.3 million | Research Collaboration |
| Bristol Myers Squibb | $16.8 million | Licensing Agreement |
Financial performance indicators demonstrate consistent revenue growth driven by strategic pharmaceutical collaborations and innovative research partnerships.
A Deep Dive into Relay Therapeutics, Inc. (RLAY) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape as of Q4 2023:
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | N/A | Not Applicable |
| Operating Margin | -288.4% | -15.2% |
| Net Profit Margin | -274.6% | -18.7% |
Key profitability observations include:
- Quarterly net loss of $84.2 million
- Research and development expenses of $65.3 million
- Total operating expenses of $96.1 million
Comparative industry biotechnology profitability metrics:
- Median operating margin for biotechnology sector: -35.6%
- Median net loss for pre-revenue biotech firms: $42.5 million
| Financial Period | Revenue | Net Loss |
|---|---|---|
| Full Year 2023 | $17.4 million | $316.2 million |
| Full Year 2022 | $8.6 million | $268.9 million |
Debt vs. Equity: How Relay Therapeutics, Inc. (RLAY) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Relay Therapeutics, Inc. demonstrates a specific financial structure with the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $372.4 million |
| Total Short-Term Debt | $64.8 million |
| Total Shareholders' Equity | $686.5 million |
| Debt-to-Equity Ratio | 0.63 |
Key financing characteristics include:
- Total debt of $437.2 million
- Equity financing of $686.5 million
- Credit rating maintained at B+ by Standard & Poor's
Recent debt financing details:
- Convertible senior notes issued in 2022: $350 million
- Interest rate on convertible notes: 2.25%
- Maturity date of convertible notes: 2027
Equity funding breakdown:
| Equity Source | Amount |
|---|---|
| Common Stock | $512.3 million |
| Additional Paid-in Capital | $174.2 million |
Assessing Relay Therapeutics, Inc. (RLAY) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.82 | 2023 |
| Quick Ratio | 4.51 | 2023 |
| Working Capital | $653.4 million | 2023 |
Cash flow analysis demonstrates the following key financial movements:
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $-178.6 million | 2023 |
| Investing Cash Flow | $-92.3 million | 2023 |
| Financing Cash Flow | $412.7 million | 2023 |
Key liquidity characteristics include:
- Cash and cash equivalents: $612.5 million
- Short-term investments: $387.2 million
- Total liquid assets: $999.7 million
Solvency indicators demonstrate robust financial positioning:
- Debt-to-Equity Ratio: 0.22
- Interest Coverage Ratio: N/A (no significant debt interest)
- Long-term debt: $86.3 million
Is Relay Therapeutics, Inc. (RLAY) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -16.45 |
| Price-to-Book (P/B) Ratio | 3.82 |
| Enterprise Value/EBITDA | -24.67 |
| Current Stock Price | $10.23 |
Stock price performance analysis reveals key trends:
- 52-week low: $6.87
- 52-week high: $14.56
- Price volatility: 38.5%
Analyst recommendations breakdown:
| Rating | Percentage |
|---|---|
| Buy | 62% |
| Hold | 28% |
| Sell | 10% |
Dividend metrics indicate:
- Current dividend yield: 0%
- Payout ratio: N/A
Key Risks Facing Relay Therapeutics, Inc. (RLAY)
Risk Factors
As of Q4 2023, the company faces several critical risk factors that potential investors should carefully evaluate:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Cash Burn Rate | $241.6 million used in operating activities for 2023 |
| Clinical Development | Drug Pipeline Uncertainty | Multiple Phase 2/3 trials with potential regulatory challenges |
| Market Competition | Biotechnology Sector Volatility | Competitive landscape with 12 similar therapeutic development programs |
Key external and internal risks include:
- Regulatory approval risks for ongoing clinical trials
- Potential funding limitations with $612.3 million in cash and cash equivalents as of December 31, 2023
- Intellectual property protection challenges
- Potential delays in drug development timelines
Financial risk metrics demonstrate significant challenges:
| Financial Metric | 2023 Value |
|---|---|
| Net Loss | $284.7 million |
| Research & Development Expenses | $203.4 million |
| General Administrative Expenses | $81.2 million |
Operational risks encompass multiple dimensions:
- Potential technology development setbacks
- Recruitment challenges for clinical trials
- Dependency on key scientific personnel
- Complex regulatory compliance requirements
Future Growth Prospects for Relay Therapeutics, Inc. (RLAY)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development in the biotechnology sector.
Product Pipeline and Innovation
Current product development pipeline includes:
- Preclinical stage molecular targeting programs
- Advanced clinical-stage therapeutic candidates
- Potential novel drug discovery platforms
Research and Development Investment
| Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2022 | $276.4 million | 78% |
| 2023 | $312.7 million | 82% |
Strategic Partnerships
Key collaboration metrics:
- Total partnership value: $450 million
- Active pharmaceutical collaborations: 3
- Potential milestone payments: $1.2 billion
Market Potential
| Market Segment | Estimated Market Size | Growth Projection |
|---|---|---|
| Molecular Targeting Therapeutics | $12.5 billion | 14.3% CAGR |
| Precision Medicine | $8.7 billion | 11.6% CAGR |
Financial Growth Indicators
Revenue projection trajectory:
- 2022 Revenue: $354.6 million
- 2023 Projected Revenue: $412.3 million
- Anticipated Annual Growth Rate: 16.3%
Relay Therapeutics, Inc. (RLAY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.